BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Intelliject, Inc. Announces $15 Million Debt Financing to Accelerate Targeted Pipeline Development


5/30/2012 6:40:45 AM

RICHMOND, Va.--(BUSINESS WIRE)-- Intelliject, Inc., a specialty pharmaceutical company pioneering the next generation of drug/device combination products, today announced that it has entered into a $15 million debt facility with Hercules Technology Growth Capital, Inc. (HTGC) to enable Intelliject to accelerate the development of key pipeline products. Hercules is a leading specialty finance company providing customized debt financing for entrepreneurial venture capital and private-equity backed companies in technology-related markets including cleantech and life science.

These funds will enable Intelliject to fund the development of select pipeline products simultaneously with final preparation for the launch of its lead product, e-cue™, in North America through its partner, Sanofi.

Commenting on the new financing, Spencer Williamson, President and CEO of Intelliject, said, “Hercules is a top tier financial partner and we are pleased with this debt capital facility which enables Intelliject to immediately advance the product development program for our exciting pipeline.”

Chad Norman, Hercules Managing Director, said, “We have been closely following Intelliject and have been impressed with the progress they have made on their lead product, e-cue™. We are now excited to support Intelliject’s targeted pipeline development.”

ABOUT INTELLIJECT, INC.:

Intelliject is a specialty pharmaceutical company dedicated to developing drug/device combination products that empower patients to gain freedom from their medical conditions. Each Intelliject product combines an established drug with an innovative delivery platform with the goal of achieving superiority, patient preference and cost effectiveness.

Intelliject applies rigorous selection criteria to identify areas where its patient-centric approach and proprietary technology will offer superior solutions. The company only proceeds to an active development program once it has established that incremental clinical and economic benefit is achievable.

Intelliject is a privately-held company headquartered in Richmond, Virginia.

For online information please visit www.intelliject.com.

ABOUT HERCULES TECHNOLOGY GROWTH CAPITAL, INC:

Hercules Technology Growth Capital (HTGC), is a specialty finance firm providing customized loans to public and private technology-related companies, including clean technology, life science and select lower middle market technology companies at all stages of development. Since inception, Hercules has committed more than $2.8 billion to over 200 companies and is the lender of choice for entrepreneurs, venture capital and private equity firms seeking ideal, customized growth capital financing at all stages of a company's development to accelerate business growth and reach the next critical milestone. Hercules common stock trades on the NYSE under the ticker symbol "HTGC". In addition, the Company's 7.00% Senior Notes due 2019 trade on the NYSE under the symbol "HTGZ". For more information, please visit www.htgc.com.

Intelliject Disclaimer: In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Intelliject's current expectations or forecasts of future events. These may include statements regarding anticipated development of potential products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products;and other statements regarding matters that are not historical facts. Some of these forward-looking statements may be identified by the use of words in the statements such as "estimate," "intend," or other words and terms of similar meaning. Statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Intelliject cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Intelliject undertakes no obligations to update or revise these statements, except as may be required by law.

Contact:

for Intelliject, Inc. April Sciacchitano, 757-640-1982

asciacchitano@crt-tanaka.com



Read at BioSpace.com
Read at News Release
Read at Private Equity Hub

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES